Patents by Inventor Shaker A. Mousa

Shaker A. Mousa has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10961204
    Abstract: Chemical compounds/compositions, methods of synthesis, and methods of use. The compounds/compositions are directed toward thyrointegrin antagonists conjugated to a polymer. The compounds/compositions further comprise an additional substituent also conjugated to the polymer. The compounds/compositions demonstrate increased uptake across the blood brain barrier along with increased retention therein and retention within tumor. The compounds/compositions may also include improved synthesis scalability, improved purity, improved aqueous solubility, and a solid product or intermediate. The compounds/compositions may demonstrate improved antiangiogenic effect and improved efficacy against conditions, particularly cancers, requiring blood brain barrier permeability, for example, glioblastoma (GBM).
    Type: Grant
    Filed: April 29, 2020
    Date of Patent: March 30, 2021
    Assignee: NANOPHARMACEUTICALS LLC
    Inventors: Shaker A. Mousa, Bruce A. Hay
  • Patent number: 10947220
    Abstract: Disclosed are compounds that modulate the physiological action of the proprotein convertase subtilisin kexin type 9 (PCSK9), as well as therapeutic methods for use of such compounds to reduce LDL-cholesterol levels and/or for the treatment and/or prevention of cardiovascular disease (CVD), including treatment of hypercholesterolemia.
    Type: Grant
    Filed: May 6, 2020
    Date of Patent: March 16, 2021
    Assignee: SHIFA BIOMEDICAL CORPORATION
    Inventors: Sherin Salaheldin Abdel-Meguid, Nabil A. Elshourbagy, Harold V. Meyers, Shaker A. Mousa
  • Patent number: 10899748
    Abstract: Disclosed are compounds that modulate the physiological action of the proprotein convertase subtilisin kexin type 9 (PCSK9), as well as therapeutic methods for use of such compounds to reduce LDL-cholesterol levels and/or for the treatment and/or prevention of cardiovascular disease (CVD), including treatment of hypercholesterolemia.
    Type: Grant
    Filed: June 19, 2017
    Date of Patent: January 26, 2021
    Assignee: SHIFA BIOMEDICAL CORPORATION
    Inventors: Sherin Salaheldin Abdel-Meguid, Nabil A. Elshourbagy, Harold V. Meyers, Shaker A. Mousa
  • Publication number: 20200262822
    Abstract: Disclosed are compounds that modulate the physiological action of the proprotein convertase subtilisin kexin type 9 (PCSK9), as well as therapeutic methods for use of such compounds to reduce LDL-cholesterol levels and/or for the treatment and/or prevention of cardiovascular disease (CVD), including treatment of hypercholesterolemia.
    Type: Application
    Filed: May 6, 2020
    Publication date: August 20, 2020
    Inventors: Sherin Salaheldin Abdel-Meguid, Nabil A. Elshourbagy, Harold V. Meyers, Shaker A. Mousa
  • Patent number: 10695436
    Abstract: Chemical compositions and methods of synthesis thereof. The compositions disclosed and described herein are directed toward and classified as anti-angiogenic thyrointegrin antagonists, which may be capable of reacting with one or more cell surface receptors of the integrin ?v?3 receptor family. Anti-angiogenic thyrointegrin antagonists or derivatives thereof are conjugated via a non-cleavable linker having an amine, diamine or triazole linkage to polymers of Polyethylene Glycol, cyclodextrin, chitosan, alginic acid or hyaluronic acid, forming a single chemical entity.
    Type: Grant
    Filed: December 18, 2018
    Date of Patent: June 30, 2020
    Assignee: NANOPHARMACEUTICALS, LLC
    Inventors: Shaker A. Mousa, Mehdi Rajabi
  • Publication number: 20190314314
    Abstract: Chemical compositions and methods of synthesis thereof. The compositions disclosed and described herein are directed toward thyroid hormone ?v?3 integrin receptor antagonists conjugated to targets of the norepinephrine transporter (NET) or the catecholamine transporter. The compositions have a dual targeting effect and increased targeting efficiency in the treatment and diagnostic imaging of neuroendocrine tumors.
    Type: Application
    Filed: April 30, 2019
    Publication date: October 17, 2019
    Inventors: Shaker Mousa, Mehdi Rajabi, Ozlem O. Karakus
  • Publication number: 20190270729
    Abstract: Disclosed are compounds that modulate the physiological action of the proprotein convertase subtilisin kexin type 9 (PCSK9), as well as therapeutic methods for use of such compounds to reduce LDL-cholesterol levels and/or for the treatment and/or prevention of cardiovascular disease (CVD), including treatment of hypercholesterolemia.
    Type: Application
    Filed: June 19, 2017
    Publication date: September 5, 2019
    Inventors: Sherin Salaheldin Abdel-Meguid, Nabil A. Elshourbagy, Harold V. Meyers, Shaker A. Mousa
  • Patent number: 10328043
    Abstract: Chemical compositions and methods of synthesis thereof. The compositions disclosed and described herein are directed toward thyroid hormone ?v?3 integrin receptor antagonists conjugated to targets of the norepinephrine transporter (NET) or the catecholamine transporter. The compositions have a dual targeting effect and increased targeting efficiency in the treatment and diagnostic imaging of neuroendocrine tumors.
    Type: Grant
    Filed: April 11, 2018
    Date of Patent: June 25, 2019
    Assignee: NANOPHARMACEUTICALS, LLC.
    Inventors: Shaker Mousa, Mehdi Rajabi, Ozlem O. Karakus
  • Publication number: 20190125684
    Abstract: Nanocapsules of bioactive compounds derived from natural products as an adjunct treatment for cancer. Nanocapsules of bioactive compounds showed synergy in the treatment of cancer therapy-induced toxicity.
    Type: Application
    Filed: November 2, 2017
    Publication date: May 2, 2019
    Applicant: King Abdulaziz University
    Inventors: Amna Ali Nasser SADDIQ, Shaker Ahmad MOUSA, Deena Shaker MOUSA
  • Publication number: 20190111145
    Abstract: Chemical compositions and methods of synthesis thereof. The compositions disclosed and described herein are directed toward and classified as anti-angiogenic thyrointegrin antagonists, which may be capable of reacting with one or more cell surface receptors of the integrin ?v?3 receptor family. Anti-angiogenic thyrointegrin antagonists or derivatives thereof are conjugated via a non-cleavable linker having an amine, diamine or triazole linkage to polymers of Polyethylene Glycol, cyclodextrin, chitosan, alginic acid or hyaluronic acid, forming a single chemical entity.
    Type: Application
    Filed: December 18, 2018
    Publication date: April 18, 2019
    Inventors: Shaker A. Mousa, Mehdi Rajabi
  • Patent number: 10259804
    Abstract: Endothelial Lipase (EL) inhibitors and methods of using such inhibitors for treating conditions implicating EL are provided herein. The present invention meets the needs in the field by providing small molecule inhibitors of EL function that can be used therapeutically to raise HDL cholesterol levels in blood, and can be used in the prevention and/or treatment of cholesterol and lipoprotein metabolism disorders, including, but not limited to, familial hypercholesterolemia, atherogenic dyslipidemia, atherosclerosis, and, more generally, cardiovascular disease (CVD).
    Type: Grant
    Filed: September 23, 2015
    Date of Patent: April 16, 2019
    Assignee: SHIFA BIOMEDICAL CORPORATION
    Inventors: Nabil Elshourbagy, Shaker Mousa, Harold Meyers
  • Patent number: 10251842
    Abstract: Nanocapsules of bioactive compounds derived from natural products as an adjunct treatment for cancer. Nanocapsules of bioactive compounds showed synergy in the treatment of cancer therapy-induced toxicity.
    Type: Grant
    Filed: November 2, 2017
    Date of Patent: April 9, 2019
    Assignee: King Abdulaziz University
    Inventors: Amna Ali Nasser Saddiq, Shaker Ahmad Mousa, Deena Shaker Mousa
  • Patent number: 10201616
    Abstract: Chemical compositions and methods of synthesis thereof. The compositions disclosed and described herein are directed toward and classified as anti-angiogenic thyrointegrin antagonists, which may be capable of reacting with one or more cell surface receptors of the integrin ?v?3 receptor family. Anti-angiogenic thyrointegrin antagonists or derivatives thereof are conjugated via a non-cleavable linker having an amine, diamine or triazole linkage to polymers of Polyethylene Glycol, cyclodextrin, chitosan, alginic acid or hyaluronic acid, forming a single chemical entity.
    Type: Grant
    Filed: June 7, 2017
    Date of Patent: February 12, 2019
    Assignee: NANOPHARMACEUTICALS, LLC
    Inventors: Shaker A. Mousa, Mehdi Rajabi
  • Patent number: 10131637
    Abstract: Disclosed are compounds of the class of 2-phenylacetamides that modulate the physiological action of the proprotein convertase subtilisin kexin type 9 (PCSK9), and methods of using these modulators to reduce LDL-cholesterol levels and/or for the treatment and/or prevention of cardiovascular disease (CVD), including treatment of hypercholesterolemia.
    Type: Grant
    Filed: March 11, 2014
    Date of Patent: November 20, 2018
    Assignees: Shifa Biomedical Corporation, Temple University—Of The Commonwealth System of Higher Education
    Inventors: Sherin Salaheldin Abdel-Meguid, Magid Abou-Gharbia, Benjamin Blass, Wayne Childers, Nabil Elshourbagy, Victor Ghidu, Rogelio Martinez, Harold Meyers, Shaker A. Mousa
  • Patent number: 10130686
    Abstract: Thyroid hormone antagonists and their nanoparticle formulations (Nanotetrac™ or Nanotriac™) act at a cell surface receptor to block angiogenesis and tumor cell proliferation. The complex anti-angiogenic performs actions on specific cytokines and chemokines. Thyroid hormone antagonists inhibit expression in tumor cells of cytokine genes, e.g., specific interleukins, and chemokine genes, such as fractalkine (CX3CL1), and chemokine receptor genes (CX3CR1) that are targets in the development of inflammation-suppressant drugs. This application discloses a novel composition of Tetra or Tri-iodothyroacetic acid (tetrac or triac), other thyroid partial agonists or antagonists and their nanoparticle formulations conjugated to polymers and encapsulating non-steroidal anti-inflammatory, anti-inflammatory glucocorticoids, and/or polyphenols for the management of various acute and chronic inflammatory disorders ranging from neurological, vascular, and musculoskeletal disorders.
    Type: Grant
    Filed: November 21, 2016
    Date of Patent: November 20, 2018
    Assignee: NANOPHARMACEUTICALS LLC
    Inventors: Shaker A. Mousa, Paul J. Davis
  • Patent number: 10060934
    Abstract: A method for screening a patient for angioinhibition resistance and treating said patient having a disease susceptible to treatment via an anti-angiogenic agent. The screening method includes an assay for identifying the presence of angioinhibition resistance in patients by collecting patient blood or serum and subjecting it to a Chick Chorioallantoic Membrane (CAM) angiogenesis assay configured for accepting a human tumor wherein the human tumor xenograft includes a vasculature system. The screening method and assay further includes steps that include using the CAM results for identifying the endogenous pro-angiogenic non-peptide hormone concentrations of the blood sample by calculating the vascular activity of the vasculature system of the human tumor xenograft in the presence of anti-angiogenic drugs and inducing in the patient, a state of subclinical hypothyroidism prior to commencing anti-angiogenic treatment.
    Type: Grant
    Filed: November 18, 2014
    Date of Patent: August 28, 2018
    Assignee: NANOPHARMACEUTICALS LLC
    Inventors: Shaker A. Mousa, Paul J. Davis
  • Patent number: 10046005
    Abstract: A composition and associated method for treating a hepatitis C virus (HCV) infection in a subject who is human being. The composition includes: an anti-viral agent and/or a protease inhibitor; a polymerase inhibitor; one or more viral entry inhibitors; and one or more anti-fibrotic agents and/or anti-hemolytic agents including one or more Polyphenols and/or one or more Thiols. The composition may also include one or more sulfated oligosaccharide or non-anticoagulant glycosaminoglycans (GAGs). The method administers, to the subject, a therapeutic dose of the composition to treat the subject for the HCV infection.
    Type: Grant
    Filed: August 11, 2016
    Date of Patent: August 14, 2018
    Inventor: Shaker A. Mousa
  • Patent number: 9980933
    Abstract: Disclosed are methods of treating subjects having conditions related to angiogenesis including administering an effective amount of a polymeric form of thyroid hormone, or an antagonist thereof, to promote or inhibit angiogenesis in the subject. Compositions of the polymeric forms of thyroid hormone, or thyroid hormone analogs, are also disclosed.
    Type: Grant
    Filed: August 26, 2013
    Date of Patent: May 29, 2018
    Assignee: NANOPHARMACEUTICALS LLC
    Inventors: Shaker A. Mousa, Faith B. Davis, Paul J. Davis
  • Patent number: 9956291
    Abstract: A composition and an associated method for hepatic targeted delivery of thyroid receptor beta1 (TR?1) agonist to a liver of a subject. The composition includes hydrophobic nanoparticles, a liver targeting moiety exterior to each nanoparticle and covalently bonded to each nanoparticle, and at least one TR?1 agonist encapsulated within each nanoparticle. The nanoparticles include chitosan hybrid nanoparticles, amine-modified PLGA nanoparticles, solid lipid nanoparticles, and combinations thereof. The liver targeting moiety includes Glycyrrhetinic acid (GA), Lactobionic acid (LA), or combinations thereof.
    Type: Grant
    Filed: July 10, 2013
    Date of Patent: May 1, 2018
    Inventor: Shaker A. Mousa
  • Patent number: 9956181
    Abstract: A nano-composition and a method of using the composition. The composition includes nanoparticles. Each nanoparticle includes a shell encapsulating lycopene. The shell includes oligomerized (?)-epigallocatechin-3-O-gallate (OEGCG) electrostatically bonded to chitosan. The method of using the composition includes administering the nano-composition to a human being.
    Type: Grant
    Filed: September 9, 2016
    Date of Patent: May 1, 2018
    Inventors: Shaker A. Mousa, Mohammed H. Qari, Mohammed-Salleh M. Ardawi